Efficiency of recombinant human TNF in human cancer therapy

Cancer Immunity

Volumn 6, Issue , 2006, Pages

  Lejeune, Ferdy J ^a,b,c   Liénard, Danielle ^a,b   Matter, Maurice ^c   Rüegg, Curzio ^a,d  

^a Multidisciplinary Oncology Center (CePO)   (Switzerland)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d National Center of Competence in Research in Molecular Oncology   (Switzerland)

Author keywords

Human; Isolated limb perfusion; Melphalan; Neoplasms; Survival rate; TNF

Indexed keywords

DOXORUBICIN; GAMMA INTERFERON; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR;

CANCER CLASSIFICATION; CANCER SURVIVAL; CANCER THERAPY; CELL ADHESION; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM CELL; FOLLOW UP; HUMAN; HYPOTENSION; KIDNEY DISEASE; LIMB PERFUSION; LIMB SALVAGE; LIVER DISEASE; LIVER PERFUSION; LUNG DISEASE; MELANOMA; NONHUMAN; REVIEW; SHOCK; SOFT TISSUE SARCOMA;

EID: 33744955317     PISSN: 14249634     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Review

References (143)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl 16): 15-8.
2. Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 630-2.
3. Oettgen HF, Carswell EA, Kassel RL, Fiore N, Williamson B, Hoffmann MK, Haranaka K, Old LJ. Endotoxin-induced tumor necrosis factor. Recent Results Cancer Res 1980; 75: 207-12.
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72: 3666-70.
5. Cerami A, Ikeda Y, Le Trang N, Hotez PJ, Beutler B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 1985; 11: 173-7.
6. Killar L, White J, Black R, Peschon J. Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann N Y Acad Sci 1999; 878: 442-52.
7. Dembic Z, Loetscher H, Gubler U, Pan YC, Lahm HW, Gentz R, Brockhaus M, Lesslauer W. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 1990; 2: 231-7.
8. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74:845-53.
9. Grell M, Zimmermann G, Hulser D, Pfizenmaier K, Scheurich P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J Immunol 1994; 153: 1963-72.
10. Lin Y, Devin A, Rodriguez Y, Liu ZG. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 1999; 13: 2514-26.
11. Song HY, Regnier CH, Kirschning CJ, Goeddel DV, Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci U S A 1997; 94: 9792-6.
12. Hsu H, Shu HB, Pan MG, Goeddel DV TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299-308.
13. Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol 1999; 19: 350-64.
14. Wong GH, Goeddel DV. Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J Immunol 1994; 152: 1751-5.
15. Vancompernolle K, Boonefaes T, Mann M, Fiers W. Grooten J. Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death. J Biol Chem 2000; 275: 33876-82.
16. Denecker G, Vercammen D, Steemans M, Vanden Berghe T, Brouckaert G, Van Loo G, Zhivotovsky B, Fiers W Grooten J, Declercq W Vandenabeele P. Death receptor-induced apoptotic and necrotic cell death: differential role of caspases and mitochondria. Cell Death Differ 2001; 8: 829-40.
17. Fiers W, Beyaert R, Brouckaert P, Everaerdt B, Haegeman G, Suffys P, Tavernier J, Vandenabeele P, Vanhaesebroeck B, Van Ostade X, Van Roy F. Gene cloning and structure - function relationship of cytokines such as TNF and interleukins. Immunol Lett 1987; 16: 219-26.
18. Jones EY, Stuart DI, Walker NP. Crystal structure of TNF. Immunol Ser 1992; 56: 93-127.
19. Tracey KJ, Lowry SF, Cerami A. The pathophysiologic role of cachectin/TNF in septic shock and cachexia. Ann Inst Pasteur Immunol 1988; 139: 311-7.
20. Lin WJ, Yeh WC. Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 2005; 24: 206-9.
21. Taguchi T, Sohmura Y. Clinical studies with TNF. Biotherapy 1991; 3: 177-86.
22. Taguchi T. Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050). Cancer Detect Prev 1988; 12: 561-72.
23. Saks S, Rosenblum M. Recombinant human TNF-alpha: preclinical studies and results from early clinical trials. Immunol Ser 1992; 56: 567-87.
24. Creaven PJ, Brenner DE, Cowens JW, Huben RP, Wolf RM, Takita H, Arbuck SG, Razack MS, Proefrock AD. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 1989; 23: 186-91.
25. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 1988; 62: 2467-71.
26. Schiller JH, Storer BE, Witt PL, Alberti D, Tombes MB, Arzoomanian R, Proctor RA, McCarthy D, Brown RR, Voss SD. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res 1991; 51: 1651-8.
27. Lenk H, Tanneberger S, Muller U, Ebert J, Shiga T. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1989; 24: 391-2.
28. Skillings J, Wierzbicki R, Eisenhauer E, Venner P, Letendre F, Stewart D, Weinerman B. A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Immunother 1992; 11: 67-70.
29. Maruno M, Yoshimine T, Nakata H, Nishioka K, Kato A, Hayakawa T. Complete regression of anaplastic astrocytoma by intravenous tumor necrosis factor-alpha (TNF alpha) after recurrence: a case report. Surg Neurol 1994; 41: 482-5.
30. Balkwill FR, Ward BG, Moodie E, Fiers W. Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer. Cancer Res 1987; 47: 4755-8.
31. Takahashi N, Fiers W, Brouckaert P. Anti-tumor activity of tumor necrosis factor in combination with interferon-gamma is not affected by prior tolerization. Int J Cancer 1995; 63: 846-54.
32. Mareel M, Dragonetti C, Tavernier J, Fiers W. Tumor-selective cytotoxic effects of murine tumor necrosis factor (TNF) and interferon-gamma (IFN-gamma) in organ culture of B16 melanoma cells and heart tissue. Int J Cancer 1988; 42: 470-3.
33. Rosen P. The synergism of gamma-interferon and tumor necrosis factor in whole body hyperthermia with vitamin C to control toxicity. Med Hypotheses 1992; 38: 257-8.
34. Haranaka K, Sakurai A, Satomi N. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy, or immunotherapy. J Biol Response Mod 1987; 6: 379-91.
35. Niitsu Y, Watanabe N, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res 1988; 48: 654-7.
36. Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988; 48: 650-3.
37. Amano T, Kumini K, Nakashima K, Uchibayashi T, Hisazumi H. A combined therapy of hyperthermia and tumor necrosis factor for nude mice bearing KK-47 bladder cancer. J Urol 1990; 144(2 Pt 1): 370-4.
38. Hiraoka M, Li YP, Tsutsui K, Abe M, Miyachi Y. Effects of tumor necrosis factor and hyperthermia on Meth-A tumors. Jpn J Cancer Res 1991; 82: 1171-4.
39. Hachiya T, Okada K, Sakurai A, Satomi N, Haranaka K. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia against heterotransplanted human prostatic carcinoma and its lymph node metastasis in nude mice. Mol Biother 1992; 4: 34-9.
40. Ohno S, Strebel FR, Stephens LC, Siddik ZH, Makino M, Klostergaard J, Tomasovic SP, Khokhar AR, Bull JM. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats. Cancer Res 1992; 52: 4096-101.
41. Mayer J, Hajek R, Vorlicek J, Tomiska M. Sepsis and septic shock. I. Definitions and pathophysiology. Support Care Cancer 1995; 3: 106-10.
42. De Blasi RA, Palmisani S, Alampi D, Mercieri M, Romano R, Collini S, Pinto G. Microvascular dysfunction and skeletal muscle oxygenation assessed by phase-modulation near-infrared spectroscopy in patients with septic shock. Intensive Care Med 2005; 31: 1661-8.
43. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998; 10: 573-80.
44. Lejeune F. [Locoregional use of TNF (tumor necrosis factor) in the treatment of malignant melanoma]. Pathol Biol (Paris) 1990; 38: 883-4.
45. Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992; 16: 234-40.
46. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
47. Lejeune F, Lienard D, Eggermont A, Schraffordt Koops H, Rosenkaimer F, Gerain J, Klaase J, Kroon B, Vanderveken J, Schmitz P. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. J Infus Chemother 1995; 5: 73-81.
48. Lejeune FJ, Deloof T, Ewalenko P, Fruhling J, Jabri M, Mathieu M, Nogaret JM, Verhest A. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res 1983; 86: 268-76.
49. Koops HS, Garbe C, Hohenberger P. Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile? Eur J Cancer 1996; 32A: 1633-40.
50. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004; 139: 1237-42.
51. Eggermont AM. Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. Surg Oncol Clin N Am 2003; 12: 469-83.
52. Posner MC, Lienard D, Lejeune FJ, Rosenfelder D, Kirkwood J. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am 1995; 1: 274.
53. Lejeune F, Lienard D, Eggermont A, Schraffordt Koops H, Rosenkaimer F, Gerain J, Klaase J, Kroon B, Vanderveken J, Schmitz P. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem 1994; 56: 52-61.
54. van Ginkel RJ, Limburg PC, Piers DA, Koops HS, Hoekstra HJ. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 2002; 9: 355-63.
55. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993; 150: 2007-17.
56. Lienard D, Eggermont AM, Schraffordt Koops H, Kroon BB, Rosenkaimer F, Autier P, Lejeune FJ. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994; 4 Suppl 1: 21-6.
57. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14: 479-89.
58. Kettelhack C, Hohenberger P, Schlag PM. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor]. Langenbecks Arch Chir Suppl Kongressbd 1996; 113: 127-9.
59. Abu-Abid S, Gutman M, Lev D, Inbar M, Chaitchik S, Sorkine P, Rudick V, Meller I, Klausner JM. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs]. Harefuah 1996; 131: 227-32, 296, 295.
60. Grunhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004; 240: 939-47; discussion 947-8.
61. Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, Schmitz P, Clarke J, Steinmann G, Rosenkaimer F, Lejeune FJ. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502.
62. Fraker DL. Management of Malignant Melanoma: Local Recurrence and In-Transit Metastases. In: ASCO, editor. ASCO 2004 Educational Book. New Orleans (LA): American Society of Clinical Oncology (ASCO); 2004. p. 525-530.
63. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906-12.
64. Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion - comparison between the effects of perfusion with rhTNF alpha and a 'triple-drug regimen. Eur J Cancer 1997; 33: 596-601.
65. Grunhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005; 12: 609-15.
66. Stotter A. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992; 216: 615-6.
67. Gustafson P, Rooser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 1991; 67: 2083-6.
68. Cany L, Bui NB, Stockle E, Coindre JM, Kantor G, Ravaud A. [Neoadjuvant chemotherapy and combined conservative treatment of soft tissue sarcoma in the adult]. Bull Cancer 1992; 79: 1077-85.
69. Rahoty P, Konya A. Results of preoperative neoadjuvant chemotherapy and surgery in the management of patients with soft tissue sarcoma. Eur J Surg Oncol 1993; 19: 641-5.
70. Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14: 2653-65.
71. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-64; discussion 764-5.
72. Santinami M, Deraco M, Azzarelli A, Cascinelli F, Chiti A, Costagli V, Inglese MG, Manzi R, Quagliolo V, Rebuffoni G, Santoro N, Vaglini M. Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan. Tumori 1996; 82: 579-84.
73. Lev-Chelouche D, Abu-Abeid S, Kollander Y, Meller I, Isakov J, Merimsky O, Klausner JM, Gutman M. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. J Surg Oncol 1999; 70: 185-9.
74. Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, Meller I, Klausner JM. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997; 79: 1129-37.
75. Noorda EM, Vrouenraets BC, Nieweg OE, van Coevorden F, van Slooten GW, Kroon BB. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 2003; 98: 1483-90.
76. Eggermont AM. TNF registered in Europe: does TNF get a second chance? J Immunother 2000; 23: 505-6.
77. Lejeune FJ, Pujol N, Lienard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000; 26: 669-78.
78. Olieman AF, Pras E, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 1998; 40: 807-14.
79. Rossi CR, Foletto M, Di Filippo F, Vaglini M, Anza M, Azzarelli A, Pilati P, Mocellin S, Lise M. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 1999; 86: 1742-9.
80. Rossi CR, Vecchiato A, Foletto M, Nitti D, Ninfo V, Fornasiero A, Sotti G, Tregnaghi A, Melanotte P, Lise M. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994; 73: 2140-6.
81. Di Filippo F, Rossi CR, Vaglini M, Azzarelli A, Anza M, Santinami M, Lise M, Cavaliere F, Giannarelli D, Quagliuolo V, Vecchiato A, Deraco M, Garinei R, Foletto M, Botti C, Cavaliere R. Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother 1999; 22: 407-14.
82. Hill S, Thomas JM. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom. Melanoma Res 1994; 4 Suppl 1: 31-4.
83. Vaglini M, Santinami M, Manzi R, Inglese MG, Santoro N, Persiani L, Belli F. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res 1994; 4 Suppl 1: 35-8.
84. Bonvalot S, Laplanche A, Lejeune F, Stoeckle E, Le Pechoux C, Vanel D, Terrier P, Lumbroso J, Ricard M, Antoni G, Cavalcanti A, Robert C, Lassau N, Blay JY, Le Cesne A. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 2005; 16: 1061-8.
85. Grunhagen DJ, de Wilt JH, van Geel AN, Graveland WJ, Verhoef C, Eggermont AM. TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 2005; 31: 1011-9.
86. Olieman AF, Lienard D, Eggermont AM, Kroon BB, Lejeune FJ, Hoekstra HJ, Koops HS. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999; 134: 303-7.
87. Bickels J, Manusama ER, Gutman M, Eggermont AM, Kollender Y, Abu-Abid S, Van Geel AN, Lev-Shlush D, Klausner JM, Meller I. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999; 25: 509-14.
88. Daryanani D, de Vries EG, Guchelaar HJ, van Weerden TW, Hoekstra HJ. Hyperthermic isolated regional perfusion of the limb with carboplatin. Eur J Surg Oncol 2000; 26: 792-7.
89. Di Filippo F, Carlini S, Cavaliere F, Giannarelli D, Cavallero L, Moscarelli F, Aloe L, Cavaliere R. The role of hyperthermic perfusion in the treatment of tumors of the extremities. Adv Exp Med Biol 1990; 267: 223-34.
90. Allen RE Jr. Systemic leakage and side effects of tumor necrosis factor alpha administration via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1996; 131: 220.
91. Sorkin P, Abu-Abid S, Lev D, Gutman M, Aderka D, Halpern P, Setton A, Kudlik N, Bar-On J, Rudich V, Klausner J. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1995; 130: 1079-84.
92. Fraker DL, Alexander HR. The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results. Melanoma Res 1994; 4 Suppl 1: 27-9.
93. Lejeune FJ, Kroon BB, Di Filippo F, Hoekstra HJ, Santinami M, Lienard D, Eggermont AM. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001; 10: 821-32, ix.
94. Christoforidis D, Chassot PG, Mosimann F, Lienard D, Brunstein F, Bejko D, Lejeune FJ, Chiolero R. Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response. Arch Surg 2003; 138: 17-25.
95. Alexander HR Jr, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist 2000; 5: 416-24.
96. Alexander HR Jr, Libutti SK, Bartlett DL, Pingpank JF, Kranda K, Helsabeck C, Beresnev T. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer 2002; 95: 730-6.
97. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6: 3062-70.
98. Kresse M, Latta M, Kunstle G, Riehle HM, van Rooijen N, Hentze H, Tiegs G, Biburger M, Lucas R, Wendel A. Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors. J Immunol 2005; 175: 4076-83.
99. Yilmaz A, Bieler G, Spertini O, Lejeune FJ, Ruegg C. Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology. Int Cancer 1998; 77: 592-9.
100. Kerkar S, Williams M, Blocksom JM, Wilson RF, Tyburski JG, Steffes CP. TNF-alpha and IL-1beta Increase Pericyte/Endothelial Cell Co-Culture Permeability. J Surg Res 2005.
101. Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, Alexander HR. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 2002; 100: 1334-9.
102. Ferrero E, Zocchi MR, Magni E, Panzeri MC, Curnis F, Rugarli C, Ferrero ME, Corti A. Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am J Physiol Cell Physiol 2001; 281: C1173-9.
103. Blum MS, Toninelli E, Anderson JM, Balda MS, Zhou J, O'Donnell L, Pardi R, Bender JR. Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines. Am J Physiol 1997; 273(1 Pt 2): H286-94.
104. Petrache I, Birukova A, Ramirez SI, Garcia JG, Verin AD. The role of the microtubules in tumor necrosis factor-alpha-induced endothelial cell permeability. Am J Respir Cell Mol Biol 2003; 28: 574-81.
105. Romer LH, McLean NV, Yan HC, Daise M, Sun J, DeLisser HM. IFN-gamma and TNF-alpha induce redistribution of PECAM-1 (CD31) on human endothelial cells. J Immunol 1995; 154: 6582-92.
106. Lampugnani MG, Resnati M, Raiteri M, Pigott R, Pisacane A, Houen G, Ruco LP, Dejana E. A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J Cell Biol 1992; 118: 1511-22.
107. Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, Lejeune F, Mach JP. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993; 53: 829-36.
108. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000-3.
109. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000; 82: 973-80.
110. Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol 1991; 138: 447-53.
111. Olieman AF, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997; 4: 64-9.
112. Lassau N, Lamuraglia M, Vanel D, Le Cesne A, Chami L, Jaziri S, Terrier P, Roche A, Leclere J, Bonvalot S. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 2005; 16: 1054-60.
113. Renard N, Lienard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer 1994; 57: 656-63.
114. Renard N, Nooijen PT, Schalkwijk L, De Waal RM, Eggermont AM, Lienard D, Kroon BB, Lejeune FJ, Ruiter DJ. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 1995; 176: 279-87.
115. Ruegg C, Dormond O, Oguey D, Lejeune FJ. Tumor necrosis factor: clinical use and mechanisms of action. Drug Resist Updat 2000; 3: 271-6.
116. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408-14.
117. Ruegg C, Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 2003; 60: 1135-57.
118. Bieler G, et al. Manuscript in preparation.
119. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003; 278: 43603-14.
120. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995; 13: 264-73.
121. Gerain J, Lienard D, Pampallona S, Baumgartner M, Ruegg C, Buurman WA, Eggermont A, Lejeune F. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. Cytokine 1997; 9: 1034-42.
122. Quinn TD, Polk HC Jr, Edwards MJ. Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines. Cancer Immunol Immunother 1995; 40: 272-5.
123. Schienk S, Lienard D, Gerain J, Baumgartner M, Lejeune FJ, Chiquet-Ehrismann R, Ruegg C. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors. Int J Cancer 1995; 63: 665-72.
124. Stam TC, Swaak AJ, de Vries MR, ten Hagen TL, Eggermont AM. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000; 7: 268-75.
125. von Fliedner V. Personal communication, 1994.
126. ten Hagen TL, Seynhaeve AL, van Tiel ST, Ruiter DJ, Eggermont AM. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J Cancer 2002; 97: 115-20.
127. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A 1987; 84: 5277-81.
128. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001; 61: 711-6.
129. Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int Cancer 1996; 68: 397-405.
130. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003; 102: 4384-92.
131. Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 2004; 1028: 104-12.
132. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110: 475-82.
133. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 2006; 12: 175-82.
134. Rosenblum MG, Cheung L, Murray JL, Bartholomew R. Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun 1991; 3: 21-7.
135. Murray JL, Rosenblum MG, Lamki L, Haynie TP, Glenn HJ, Plager CE, Unger MW, Carlo DJ, Hersh EM. Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigen. NCI Monogr 1987; (3): 3-9.
136. Liu Y, Zhang W, Cheung LH, Wu Q, Li C, Rosenblum MG. The anti-gp240 fusion toxin scFvMEL/TNF shows potent antitumor activity and synergy with chemotherapeutic agents. Proc Amer Assoc Cancer Res 2005; 46 (abstract #687).
137. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, Weichselbaum RR. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-91.
138. Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996; 56: 4311-4.
139. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998; 5: 293-300.
140. Ito A, Shinkai M, Hakamada K, Honda H, Kobayashi T. Radiation-inducible TNF-alpha gene expression under stress-inducible promoter gadd 153 for cancer therapy. J Biosci Bioeng 2001; 92: 598-601.
141. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR, Weichselbaum R. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002; 9: 951-7.
142. Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR. A Phase I trial of TNFerade biologic in
143. Grunhagen DJ, de Wilt JH, Ten Hagen TL, Eggermont AM. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006; 3: 94-103.